Gene and Cell Therapy – Webinars and Online Events

Bio-Techne has extensive experience in and offers a strong and diverse portfolio for the generation, maintenance and characterization of organoids and other 3D culture systems such as spheroids.

bit.bio’s first-of-its-kind precision cellular reprogramming technology, opti-ox™, addresses the limitations of lot consistency, cell definition and scalability by controlling the precise expression of cell-fate determining genetic factors.

CRISPR/Cas9, a ground-breaking tool for altering genes with the potential to fully cure genetic diseases, has made its way into the clinic, accelerating research on new therapies using this technology.

In this webinar, Professor Marius Wernig from Stanford University and Dr. Mark Kotter, CEO and founder of bit.bio offer an expert discussion on the pioneering research of cell reprogramming.

As a cornerstone of genetic analysis in biological research, quantitative PCR (qPCR) and digital PCR (dPCR) are the most sensitive molecular methods to analyze nucleic acids and play a key role in the development of cell and gene therapies (CGT).

These tools are widely used during CGT development for example in biodistribution, pharmacokinetics and pharmacodynamics of the investigational lead molecule. But many samples, including tissues rich in nucleases, lipids and other inhibiting substances and target molecules that are short or contain modified bases, can be challenging to work with. For these types of samples, assay design using advanced strategies, concentration standards, spike-in controls and validated normalization is key for reliable analyses.

In this webinar, Dr. Kubista will present strategies for implementing reliable qPCR and dPCR analysis in CGT development while highlighting best practices for adhering to MIQE and dMIQE guidelines and the recently released ISO standard, ISO 20395:2019.

The Problem
LNPs are a valuable tool in the repertoire of gene and vaccine delivery vectors but LNP development is a complex multi-step process.

During this webinar, you will understand how capillary electrophoresis (CE) and LC-MS are being used to ensure vaccine and cell and gene therapy product quality. We will discuss how LC-MS is being used to identify impurities present in lipid nanoparticle (LNP) vaccines that have been found to deactivate mRNA. We will also cover how CE is being used in viral vector production to ensure product quality.

This Technology Networks event features exclusive talks focused on the most recent and innovative developments in the world of cell and gene therapies. Our expert speakers will highlight the opportunities cell and gene therapies provide for the treatment of disease and injury, including how cell therapies are providing novel solutions for rare diseases such as Duchenne muscular dystrophy.

The number of viral vector-based gene therapies in clinical trials has recently grown into the thousands due to the tremendous genetic disease-curing potential they harbor. Yet the comprehensive characterization of critical quality attributes for the safety and efficacy of the material produced for these trials remains a challenge for both manufacturers and regulatory bodies alike.

The rapid increase in CRISPR-mediated cell and gene therapies in clinical trials over the past few years is a testimony to the promising future of next-generation medicine.